

Severe congenital neutropenia (Kostmann Syndrome)

Severe congenital neutropenia (SCN), Kostmann syndrome is a heterogenous disorder of myelopoiesis characterized by severe chronic neutropenia, absolute neutrophil count (ANC) persistently below $0.50 \times 10^9/L$, with maturation arrest of neutrophil precursors in the bone marrow; and associated with serious recurrent bacterial infections from early infancy. Sepsis mortality is reduced by an advent of granulocyte colony stimulating factor (G-CSF) therapy. More than 90% of patients respond to G-CSF therapy. However, hematopoietic stem cell transplantation has shown promise in the treatment of non-responders. About 60-80% of SCN cases are associated with constitutive mutations in one copy of the gene encoding neutrophil elastase ELA2. Myelodysplastic syndrome and acute myeloid leukemia (MDS/AML) have been reported. The hazard of MDS/AML increases significantly overtime. Approximately 10% of patients with severe congenital neutropenia develop AML. This is not thought to be the direct result of G-CSF therapy but related to the underlying disease itself. Key Words: Myeloid leukemia, congenital neutropenia, kostmann's syndrome, myelodysplastic syndrome. Corresponding Author: Soad Khalil Al-Jaouni,. E-mail: saljaouni@kau.edu.sa

Publication: *The Egyptian Journal of Medical Human Genetics*

Author: Al-Jaouni, Soad Khalil

Date published: May 1, 2010

INTRODUCTION

Neutrophils play a vital role in protecting the body against invasion by bacteria. Severe chronic neutropenia is a general term for conditions with absolute neutrophil count (ANC) of less than $0.50 \times 10^9/L$, lasting for months or years.

Chronic neutropenia is caused by a variety of hematological, immunological, metabolic and infectious diseases¹.

The category of SCN was first clearly described by Kostmann in 1956 in Swedish kindred. An alternative name for Kostmann syndrome is infantile genetic agranulocytosis². Kostmann syndrome represents an autosomal recessive, heterogenous hematological disorders, characterized by extremely low circulating neutrophils and maturation arrest at the promyelocyte-myelocyte in the bone marrow. Neutrophil counts in these patients are typically $<0.2 \times 10^9/L$, with the majority presenting with lifethreatening infection during the first 6 months of life. SCN with similar clinical features occurs as an autosomal dominant disorder and many sporadic cases also have been reported³.

Other conditions grouped with severe congenital neutropenia (CN) include Shwachman-Diamond syndrome (SDS); inborn errors of metabolism (e.g., glycogen-storage disease, type Ib)⁴; severe combined immunodeficiency (SCID) syndromes; hyper-IgM syndrome and a few other conditions^{3,32} Patients with clinically mild disease, generally tend to have a less abnormal bone marrow. The estimated frequency of these conditions is approximately 1-2 cases per million population.

Pathophysiology:

Neutropenia refers to an ANC that is two or more standard deviations below the age related mean. Normal neutrophil levels differ according to age and race. In general, an ANC is calculated by multiplying the total leukocyte count per milliliter by the percentage of neutrophils and immature neutrophil form. In general, an ANC of 1000-1500/mm³ indicates mild neutropenia; 500-1000/mm³ indicates moderate neutropenia; and less than 500/mm³ indicates severe neutropenia. This classification is useful for predicting risk of infections.

Mortality/Morbidity:

The mortality rate is 70% within the first year of life in the absence of medical intervention with G-CSF and/or hematopoietic stem cell transplantation.

The classic Kostmann syndrome is recognized in early infancy with an equal incidence in males and females. Severe neutropenia is brought to clinical attention after an initial infection which typically occurs shortly after birth. Symptoms of Kostmann include the followings: Temperature instability in newborn period, fever, irritability and localized sites of infection.

Physical and signs of Kostmann syndrome include the followings: Oral ulcers, gingivitis, pharyngitis, sinusitis and/or otitis media, bronchitis and/or pneumonia, cellulitis, cutaneous abscess and/or boils, perianal abscess, lung or liver abscess, enteritis with chronic diarrhea and vomiting. Bacteremia and/or septicemia occur, most commonly from streptococci or staphylococci; other organisms include Pseudomonas, fungi and in rare cases Clostridium species.

Pathogenesis of congenital neutropenia:

The underlying genetic defect of SCN is still only partially understood. Some investigators have proposed that Kostmann syndrome represents a defect in the regulation or production of granulocyte colony-stimulating factor (G-CSF).

An abnormal G-CSF-induced intracellular signal transduction pathway has been suggested as a potential cause of the underlying genetic defect. Neutrophils from patients are shown to have dramatically increased levels of 2 cytosolic protein tyrosine phosphatases that contain Src-homology 2 domain (SH2 domain): Anti-Src Homology Phosphatase- 1 (SHP-1) and Src Homology Phosphatase 2 (SHP2). One hypothesis is that over expression of these proteins, which are involved in cytokine receptor signaling, plays a role in altering intracellular signal transduction processes.

A selective decrease of B-Cell Lymphoma- 2 (BCL-2) expression in myeloid cells and an increase in apoptosis in bone marrow progenitor cells have been observed. The primary function of BCL-2, a mitochondria-targeted protein, is the

prevention of Cytochrome release. Cytochrome has the capability of activating a cytosolic caspases cascade. Caspases are integral proteolytic enzymes involved in cellular apoptosis. They are activated through one of two pathways:

1. An extrinsic, death receptor-dependent pathway or.
2. An intrinsic, mitochondria-dependent pathway. Mitochondrial release of Cytochrome c serves to initiate the cytosolic caspases cascade through the second pathway. The decreased BCL-2 results in an enhanced release of Cytochrome c, which then perpetuates the caspases cascade leading to more pronounced apoptosis.

In Kostmann syndrome, the G-CSF receptors are expressed on myeloid cells in slightly increased numbers and the binding affinity for G-CSF to its receptors is normal. This is in contrary to the original theory that the underlying Kostmann defect was related to either decreased G-CSF production or diminished binding of G-CSF to its receptor.⁵

The Severe Chronic Neutropenia International Registry (SCNIR) is an important resource for studies on genetic and molecular bases for disorders causing severe chronic neutropenia.

Approximately 60-80% of SCN cases are associated with inherited or spontaneous point mutation in one copy of the gene encoding neutrophil elastase ELA2. This mutation is found in the analysis of congenital neutropenia (CN) families with autosomal dominant inheritance.

Although neutrophil elastase mutations have been found in a subgroup of patients with Kostmann syndrome, as in cyclic neutropenia. Adverse events include the development of acute myeloid leukemia in approximately 7% of the patients within the cohort of patients with Kostmann's syndrome suggesting that congenital neutropenia is a preleukemia syndrome. None of the patients with cyclic or idiopathic neutropenia developed leukemia.^{1, 6}

A subset of SCN patients harbor acquired somatic mutations in the CSF3R gene; encoding the granulocyte colony-stimulating factor receptor (G-CSF-R), which has shown a strong predisposition to acute myeloid leukemia^{7, 8}. These mutations truncate the intracellular domain, producing strong hyper-proliferation, but with defective maturation due to defective internalization and loss binding sites for several negative regulators, thus lead to extended signaling especially of STAT5 (Signal transducer and activator of transcription 5)⁹⁻¹². Other studies reported a further subset of SCN patients, with constitutive mutations in the extracellular domain of the G-CSF-R that collectively act in a dominant-negative manner leading to hypo-responsiveness to G-CSF.^{13, 14}

Studies of the G-CSF gene have shown that mutations occur mainly within a critical region of the intracellular part of the receptor.^{16, 18}

Using a positional cloning approach and candidate gene evaluation in autosomal recessive severe congenital neutropenic patients (Kostmann disease) were identified a recurrent homozygous germ line mutation in HAX1. HAX1 encodes the mitochondrial protein HAX1, which has been assigned functions in signal transduction and cytoskeletal control. HAX1 is critical for maintaining the inner mitochondrial membrane potential and protecting against apoptosis in neutrophil development, HAX1 deficiency causes autosomal recessive Kostmann disease.^{15, 33}

Diagnosis:

Severe Congenital Neutropenia is usually detected in infancy after fever or signs of severe infection develop. Patients have ANC's continuously below $0.2 \times 10^9/L$; in many cases, peripheral blood neutrophils are completely absent. With infection, there may be a transient increase in neutrophils, but counts rarely increase to normal levels. Repeated differential blood counts indicate persistent ANC's within a range of 0 to $0.2 \times 10^9/L$ is required for diagnosis. Blood counts often indicate mild anemia and thrombocytosis. There is usually a two to four fold increase in blood monocytes and an increase in the blood eosinophils count

is common. IgG levels are elevated in the majority of patients. The specific immunologic competence after vaccination is normal. Blood chemistry is within the normal, age dependent range for electrolytes, kidney and liver functions. Testing for anti-neutrophil antibodies is helpful to exclude autoimmune neutropenia of infancy.

The bone marrow usually shows maturation arrest of neutrophil precursors at an early stage (Promyelocyte/myelocyte level) with few cells of the neutrophilic series. Promyelocytes often have morphologically atypical nuclei and vacuolization of cytoplasm. The absolute number of promyelocytes is slightly increased. Megakaryocytes are normal in number and morphology. In vitro growth of granulocyte macrophage progenitor cell is defective, with few colonies formed and evidence for "Maturation arrest". Cytogenetic at the time of diagnosis of CN are almost always normal. Bone marrow cytogenetics may change during the course of the disease, with monosomy 7 being the most frequent aberration in about 50% of abnormal cytogenetic results. The interval from the original finding of normal cytogenetics to the appearance of an abnormality is often several years. Abnormal cytogenetics is often associated with morphologic changes of the bone marrow indicating the development of MDS or Leukemia.

Differential Diagnosis:

The differential diagnosis of CN includes a number of congenital and acquired diseases¹⁷. The most common difficulty is determining whether the patient has cyclic neutropenia, autoimmune neutropenia of infancy, or idiopathic neutropenia. Cyclic neutropenia is diagnosed by serial measurement of blood neutrophils on at least 3 days per week for at least 6 weeks, graphing the count. Cyclic neutropenia is also a heritable disease. Family and genetic studies show that it is an autosomal dominant disorder¹⁹. An important differential diagnostic evaluation is testing for neutrophilic antibodies²⁰. Although these infants lack peripheral blood neutrophils, the marrow function is normal; maturation of myeloid precursors to mature neutrophil stage is usually observed. Neutrophil or granulocyte specific antibodies in serum are detectable using immunologic test.

Idiopathic neutropenia is a form of acquired neutropenia, it includes patients without evidence of congenital, neoplastic, or immunological causes of neutropenia, the clinical phenotype is similar to autoimmune neutropenia. Patients are categorized as having idiopathic neutropenia unless they are positive for anti neutrophil antibodies.^{21, 22}

Therapy:

Severe CN is often recognized when patients present with life-threatening infection during the few months of life and are found to have extremely low circulating neutrophils. Antibiotic therapy for these infections follows the same principles as for other patients: broad-spectrum antibiotics for severe infections until the pathogen is identified; targeted therapy for specific pathogens; administration of antibiotics until the signs and symptoms of infection have cleared. Prophylactic antibiotics may be considered, but are required infrequently since the advent of G-CSF in 1987²³. Recombinant human granulocyte colony-stimulating factor (rHuG-CSF) requires long-term daily administration to maintain clinical benefit. The ANC should not be the sole indicator of clinical efficacy. Individual adjustment of dosages on the basis of both the patient's clinical course and the ANC. The efficiency of rHuG-CSF has been demonstrated by increasing the number of neutrophils with reduction of infection^{23, 24}. In contrast, GM-CSF treatment did not lead to an increase in blood neutrophils, but only in blood eosinophils²⁵. In 1994, the SCNIR collected data from more than 600 patients with CN, results demonstrated that more than 95% responded to rHuG-CSF treatment with an increase in ANCs to $1.0 \times 10^9/L$.³ Most CN patients responded to a dose between 3 and 10 mg/kg/d.^{16,17}

Generally, rHuG-CSF should be initiated at 5 mg/kg/day, the dose should be escalated to 10 mg/kg/day and then by increments of 10 mg/kg/day at 14-day intervals if the ANC remains below $1.0 \times 10^9/L$. As soon as the ANC can be maintained at 1.0 to $1.5 \times 10^9/L$ or above, further increase in rHuG-CSF dose can be stopped since the occurrence of bacterial infection is reduced dramatically at this level. The dose of rHuG-CSF can be reduced if the ANC increases to $.5.0 \times$

109/L to keep the patient at the lowest dose necessary for maintaining sufficient neutrophil count to overcome infections.^{23, 29}

Non responders to rHuG-CSF are defined by failure to benefit at dose levels exceeding 120 mg/kg/day. Partial responders have ANCs increased to 0.5 to 1.0 x 10⁹/L but still have bacterial infections. In some patients, the dose of rHuG-CSF cannot be increased to these levels because of the large volume and frequency of injections required. Patient was refractory to standard and high dose G-CSF therapy, but responded to a combined corticosteroid/G-CSF treatment, apparently through synergistic activation of STAT5 and stimulate G-CSF-induced cell proliferation.^{26, 27}

All responding patients require significantly fewer antibiotics and fewer days of hospitalization. Hematopoietic stem cell transplantation (HSCT) remains the only currently available treatment for patients who are refractory to rHuGCSF treatment or in those with leukemic transformation.²⁸

Adverse events to rHuG-CSF therapy include mild splenomegaly, osteoporosis and malignant transformation into MDS/Leukemia. If and how G-CSF treatment impacts on these adverse events is not fully understood. The hazard of MDS/Leukemia increases significantly overtime.

In the study of Rosenberg, et al.²⁹, the hazard of MDS/AML increased significantly during the period of observation of SCN on G-CSF, from 2.9% per year after 6 years to 8.0% per year after 12 years. The cumulative incidence of MDS/AML was 21% after 10 years. The risk of MDS/AML increased with the dose of G-CSF. Less responsive patients, defined as those requiring greater than 8 mg/kg/d of G-CSF, had a cumulative incidence of MDS/AML of 40% after 10 years and compared to 11% of more responsive patients. The data were interpreted as indicating that a poor response to G-CSF defines an "at-risk" population and predicts an adverse outcome.²⁹

Conversion to MDS/AML in CN patients was associated with one or more cellular genetic abnormalities (Such as monosomy7 and as mutation or G-CSFR

mutation), which may be useful for identifying subgroups of patients at high risk. Marrow cells from approximately 75% of the severe CN cases that transformed to MDS/AML also show point mutations in the gene for the G-CSFR; resulting in a truncated C-terminal cytoplasmic region of the receptor that is crucial for maturation signaling³⁰. G-CSF therapy can cause cataract and this adverse event is dose related.³¹

CONCLUSION

The use of rHuG-CSF remains first-line treatment for most CN patients, which greatly improved patient's quality of life.

All CN patients, regardless of their treatment or response, are at risk to develop MDS/ or leukemia at an actual evidence of 11.5% and accumulative incidence of 21% after 10 years. Careful monitoring for cytogenetic abnormalities and G-CSFR mutation is necessary to initiate. Hematopoietic Stem Cell Transplant (HSCT) should be restricted to G-CSF non-respond and leukemic transformation.

ACKNOWLEDGEMENTS

The author would like to extend sincere thanks for Mrs. Susana de Guzman for her assistance in writing this article.

References:

1. Welte K and Dale D. Pathophysiology and treatment of severe chronic neutropenia. *Ann.Hematol.* 1996 72(4):158- 65.
2. Kostmann R. Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria. *Acta Paediatr.Suppl.* 1956;45(Suppl 105):1-78.
3. Welte K, Zeidler C and Dale DC. Severe congenital neutropenia. *Semin. Hematol.* 2006 43(3):189-95.

4. Schrotten H, Roesler J, Breidenbach T, Wendel U, Elsner J, Schweitzer S, et al. Granulocyte and granulocyte-macrophage colony-stimulating factors for treatment of neutropenia in glycogen storage disease type Ib. *J.Pediatr.* 1991 119(5):748-54.
5. Wriedt K, Kauder E and Mauer AM. Defective myelopoiesis in congenital neutropenia. *N.Engl.J.Med.* 1970 12;283(20):1072-7.
6. Dale DC, Person RE, Bolyard AA, Aprikyan AG, Bos C, Bonilla MA, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. *Blood* 2000 1;96(7):2317- 22.
7. Aprikyan AA, Kutuyavin T, Stein S, Aprikian P, Rodger E, Liles WC, et al. Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia. *Exp.Hematol.* 2003 31(5):372-81.
8. Ward AC. The role of the granulocyte colony-stimulating factor receptor (G-CSF-R) in disease. *Front.Biosci.* 2007;12:608-18.
9. Hunter MG and Avalos BR. Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. *Blood* 1999 15;93(2):440- 6.
10. Ward AC, van Aesch YM, Schelen AM and Touw IP. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. *Blood* 1999 15;93(2):447-58.
11. Gits J, van Leeuwen D, Carroll HP, Touw IP and Ward AC. Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors. *Leukemia* 2006 20(12):2111-8.
12. Germeshausen M, Ballmaier M and Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. *Blood* 2007 1;109(1):93-9.

13. Druhan LJ, Ai J, Massullo P, Kindwall Keller T, Ranalli MA and Avalos BR. Novel mechanism of G-CSF refractoriness in patients with severe congenital neutropenia. *Blood* 2005 15;105(2):584-91.
14. Ward AC, Gits J, Majeed F, Aprikyan AA, Lewis RS, O'Sullivan LA, et al. Functional interaction between mutations in the granulocyte colony-stimulating factor receptor in severe congenital neutropenia. *Br.J.Haematol.* 2008;142(4):653-6.
15. Klein C, Grudzien M, Appaswamy G, Germeshausen M, Sandrock I, Schaffer AA, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). *Nat. Genet.* 2007 39(1):86-92.
16. Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, et al. The Severe Chronic Neutropenia International Registry: 10-year follow-up report. *Support.Cancer Ther.* 2006;3(4):220-31.
17. Zeidler C, Boxer L, Dale DC, Freedman MH, Kinsey S and Welte K. Management of Kostmann syndrome in the G-CSF era. *Br.J.Haematol.* 2000 109(3):490-5.
18. Cassinat B, Bellanné-Chantelot C, Notz-Carrère A, Menot ML, Vaury C, Micheau M, et al. Screening for G-CSF receptor mutations in patients with secondary myeloid or lymphoid transformation of severe congenital neutropenia. A report from the French neutropenia register [7]. *Leukemia* 2004;18(9):1553-5.
19. Palmer SE, Dale DC, Livingston RJ, Wijsman EM and Stephens K. Autosomal dominant cyclic hematopoiesis: Exclusion of linkage to the major hematopoietic regulatory gene cluster on chromosome 5. *Hum.Genet.* 1994 93(2):195-7.
20. Bux J, Behrens G, Jaeger G and Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: Analysis of 240 cases. *Blood* 1998 1;91(1):181-6.

21. Boxer L and Dale DC. Neutropenia: Causes and consequences. *Semin.Hematol.* 2002 39(2):75-81.
22. Kyle RA and Linman JW. Chronic idiopathic neutropenia. A newly recognized entity? *N.Engl.J.Med.* 1968 7;279(19):1015-9.
23. Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. *Blood* 1993 15;81(10):2496-502.
24. Bonilla MA, Dale D, Zeidler C, Last L, Reiter A, Ruggeiro M, et al. Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. *Br.J.Haematol.* 1994 88(4):723-30.
25. Welte K, Zeidler C, Reiter A, Muller W, Odenwald E, Souza L, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. *Blood* 1990 1;75(5):1056-63.
26. Dror Y, Ward AC, Touw IP and Freedman MH. Combined corticosteroid/granulocyte colony-stimulating factor (G-CSF) therapy in the treatment of severe congenital neutropenia unresponsive to G-CSF: Activated glucocorticoid receptors synergize with G-CSF signals. *Exp.Hematol.* 2000 28(12):1381-9.
27. Ward AC, van Aesch YM, Gits J, Schelen AM, de Koning JP, van Leeuwen D, et al. Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (GCSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment. *J.Exp.Med.* 1999 16;190(4):497-507.
28. Zeidler C, Welte K, Barak Y, Barriga F, Bolyard AA, Boxer L, et al. Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. *Blood* 2000 15;95(4):1195-8.

29. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. *Blood* 2006 15;107(12):4628-35.
30. Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B and Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. *N.Engl.J.Med.* 1995 24;333(8):487-93.
31. Al Jaouni SK and Al Jedani H. Hematopoietic colony stimulating factors can cause cataract. *Haematologica* 2007;92(suppl 2):542.
32. Boztug K, Appaswamy G, Ashikov A, Schäffer AA, Salzer U, Diestelhorst J, et al. A syndrome with congenital neutropenia and mutations in G6PC3. *N.Engl.J.Med.* 2009;360(1):32-43.
33. Ward AC and Dale DC. Genetic and molecular diagnosis of severe congenital neutropenia. *Curr.Opin.Hematol.* 2009;16(1):9-13.

Author affiliation:

Soad Khalil Al-Jaouni.

Department of Hematology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia